Table 3

Response status in patients with emergent mutations

Nilotinib 300 mg twice daily (n = 282), nNilotinib 400 mg twice daily (n = 281), nImatinib 400 mg once daily (n = 283), n
Patients with mutations 11 11 21 
Response status    
 Treatment failure* 4 6 16 
 Suboptimal response* 6 2 5 
 Confirmed loss of MMR*† 0 2 0 
 Other*‡ 1 1 0 
Nilotinib 300 mg twice daily (n = 282), nNilotinib 400 mg twice daily (n = 281), nImatinib 400 mg once daily (n = 283), n
Patients with mutations 11 11 21 
Response status    
 Treatment failure* 4 6 16 
 Suboptimal response* 6 2 5 
 Confirmed loss of MMR*† 0 2 0 
 Other*‡ 1 1 0 
*

Patients were counted only once under the worst-case response category.

†

Loss of MMR was not considered a criterion for suboptimal response.

‡

The patient in the nilotinib 300 mg twice daily arm progressed after discontinuation of treatment, and the patient in the nilotinib 400 mg twice daily arm had an unconfirmed loss of MMR but regained MMR after that.

View Large